È¿µÕ¼Ô¤Î¤¿¤á¤Î
¥µ¥×¥ê¥á¥ó¥ÈÆüµ­

¥¹¥Þ¡¼¥È¡¦¥µ¥×¥ê¥á¥ó¥È¾ðÊó¤ò¤ªÆϤ±¤¤¤¿¤·¤Þ¤¹¡£¼õ¸³À¸¤ä¥Ó¥¸¥Í¥¹¥Þ¥ó¡¢±¿Ì¿¤ËÄ©¤à¤¢¤Ê¤¿¤Î¤ª¼ê¸µ¤Ø¡£

¥«¥Æ¥´¥ê ¡§ ¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹

ÌäÂê¡¡ µ­²±ÎϤȽ¸ÃæÎϤؤθú²Ì¤¬¡¢¤è¤ê´üÂԤǤ­¤ë¤Î¤Ï¡¢¼¡¤Î¤É¤ì¤Ç¤·¤ç¤¦¡©

£±¡¥¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤òÀݤ롣
£²¡¥¹âÎï¿Í»²¤òÀݤ롣
£³¡¥¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¹âÎï¿Í»²¤òÊ»¤»¤ÆÀݤ롣

Åú¤¨
¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¡¢¹âÎï¿Í»²¤ÈÊ»¤»¤ÆÀݤê¤Þ¤·¤ç¤¦¡£


¤­¤ç¤¦¤Ï¤½¤ó¤Ê¥¨¥Ó¥Ç¥ó¥¹¤Î¤´¾Ò²ð¤Ç¤¹¡£

¥¹¥¤¥¹¤ÇȯÇ䤵¤ì¤Æ¤¤¤ë¡ÖGincosan¡×¤òÍѤ¤¤¿µ­²±ÎÏ¡¢½¸ÃæÎÏ¡¢Ãí°ÕÎϤؤμ¸³¡£

¸¦µæ¤Ë»È¤ï¤ì¤¿ Gincosan 160mg ¤È¤Ï¡¢¤½¤ÎÀ½ÉÊ1¥«¥×¥»¥ë¤Î¤³¤È¡£

¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹60mg ¡¢¹âÎï¿Í»²100mg ¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£

²¼µ­¥ê¥ó¥¯¤Ï¡¢Gincosan¤Î¥á¡¼¥«¡¼¥µ¥¤¥È¡£
http://www.ginsanaproducts.com/our-products/gincosan.html


¤È¤³¤í¤Ç¥¤¥Á¥ç¥¦ÍդȹâÎï¿Í»²¡£

ÆüËܤΥµ¥×¥ê¤Ç¤Ï¥­¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH ¤¬¤ª¤Ê¤¸¤ß¤«¤â¤·¤ì¤Þ¤»¤ó¡£


¥­¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á ¤Ï¡¢£±¥«¥×¥»¥ë¤Ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹60mg¡¢¹âÎï¿Í»²100mg¡¢ÂçƦ¥ì¥·¥Á¥óÃê½Ðʪ¡Ê¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¡Ë50mg¡¢¥Ð¥³¥Ñ¥¨¥­¥¹40mg ¤¬Æþ¤Ã¤Æ¤¤¤Þ¤¹¡£


¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦

¥®¥ó¥³ (¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹) ¤È¹âÎï¿Í»²¤ò°ì½ï¤ËÀݼ褹¤ë¤³¤È¤Ë¤è¤ë¡¢À¸ÍýŪ¡¦Àº¿ÀŪ¸ú²Ì¤òɾ²Á¤·¤¿¸¦µæ¥ì¥Ó¥å¡¼

A systematic review of research investigationing the physiological and psychological effects of combination Ginkgo biloba and Panax ginseng into a single treatment in humans:Implications for research design and analysis

PMID: 30729756
https://www.ncbi.nlm.nih.gov/pubmed/?term=30729756


Abstract
ÇطʤÈÌÜŪ¡§¹âÎï¿Í»²¤È¥®¥ó¥³¤ÏÀΤ«¤é»ÈÍѤµ¤ì¤Æ¤¤¤ë¥Ï¡¼¥Ö¥µ¥×¥ê¥á¥ó¥È¤Ç¤¹¤¬¡¢Î×¾²Åª¥¨¥Ó¥Ç¥ó¥¹¤Ï´°Á´¤Ë¤Ï²òÌÀ¤µ¤ì¤Æ¤¤¤Þ¤»¤ó¡£

¤³¤Î£²¤Ä¤Î¥Ï¡¼¥Ö¤ò°ì½ï¤ËÆâÉþ¤¹¤ë¤³¤È¤Ë¤è¤ëÁê¾è¸ú²Ì¤òÌÀ¤é¤«¤Ë¤·¤¿¤¤¤È»×¤¤¤Þ¤¹¡£


ÊýË¡¡§²æ¡¹¤Ï¿Í¤òÂоݤȤ·¤Æ2¤Ä¤òƱ»þ¤ËÀݼ褷¤ÆÀ¸ÍýŪ¡¦Àº¿ÀŪ·ë²Ì¤Ë¤è¤ê¤½¤Î¸ú²Ì¤òÄ´ºº¤·¤¿ÏÀʸ¤òÂоݤ˥ì¥Ó¥å¡¼¤È¤¤¤¦·Á¤Ç¤Þ¤È¤á¤Þ¤·¤¿¡£¡Ê°Ê²¼¾Êά¡Ë


·ë²Ì¡§8¤Ä¤ÎÏÀʸ¤¬¸«¤Ä¤«¤ê¤Þ¤·¤¿¡£¤â¤Ã¤È¤â¤Ï¤Ã¤­¤ê¤·¤¿·ëÏÀ¤¬½Ð¤Æ¤¤¤¿¤â¤Î¤Ï¡¢´µ¼Ô¤Ø¤Î½Û´Ä´ï·Ï/¿´·ì´É·Ï¥·¥¹¥Æ¥à¤Ø¤ÎÍ­¸úÀ­¤È¡¢´µ¼Ô¤È·ò¾ï¿Í¤ËÂФ¹¤ëÆ󼡵­²±¤Ø¤Î¸ú²Ì¤Ç¤·¤¿¡£


Introduction
¹âÎï¿Í»²¤È¥®¥ó¥³¤Ï¤É¤Á¤é¤âÅÁÅýŪ¤Ê¥Ï¡¼¥Ö¥µ¥×¥ê¥á¥ó¥È¤Ç¤¹¡£

¤½¤ì¤¾¤ìñÂΤÇÍÍ¡¹¤Ê¸ú²Ì¤¬¼¨¤µ¤ì¤Æ¤ª¤ê¡¢Î㤨¤Ð¿Í»²¤ÏÃæ¿õ¿À·Ð·Ï¤Î¿À·ÐÅÁãʪ¼Á¤ËÂФ¹¤ë¸ú²Ì¤¬Êó¹ð¤µ¤ì¤Æ¤ª¤ê¡¢¤Þ¤¿¥¢¥ß¥í¥¤¥É¤ÎÄÀÃå¤òͽËɤ¹¤ë¤³¤È¤â¼¨¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

¥®¥ó¥³¤Î³èÀ­Êª¼Á¤â¤Þ¤¿¡¢Ãæ¿õ¿À·Ð·Ï¤Î¿À·ÐÅÁãʪ¼Á·ÐÏ©¤ËÂФ¹¤ë¸ú²Ì¤¬Ç§¤á¤é¤ì¤Æ¤ª¤ê¡¢Ãæ¿õ¿À·Ð·Ï¡¦Ëö¾¿¿À·Ð·Ï¤ª·ìή¤òÄ´À°¤¹¤ë¤³¤È¤â³Îǧ¤µ¤ì¤Æ¤¤¤Þ¤¹¡£¡Ê°Ê²¼¾Êά¡Ë


Results
°ìÈֺǽé¤ÎÊó¹ð¤¬1992ǯ¡¢ºÇ¶á¤ÎÊó¹ð¤¬2004ǯ¤Ç¤·¤¿¡£

¤¹¤Ù¤Æ¤ÎÊó¹ð¤¬Panax ginsengÃê½ÐʪG115 ¤ÈGinkgo bilobaÃê½ÐʪGK501¤ò»ÈÍѤ·¤Æ¤¤¤Þ¤·¤¿¡£


3.2.1 ÆâÉþ½é´ü¤Ë¤ª¤±¤ëGincosan¤È¥×¥é¥»¥Ü¤È¤Î¸ú²Ì¤ÎÈæ³Ó
Kiesewetter¤é¤¬Êó¹ð¤·¤Æ¤ª¤ê¡¢Æó½ÅÌÕÌܥץ饻¥Ü¥³¥ó¥È¥í¡¼¥ë¸òºµ»î¸³¤Î·Á¤Ç10¿Í¤ÎÈ︳¼Ô¤òÂоݤ˹ԤäƤ¤¤Þ¤¹¡£

Gincosan160mg¡ÊÃí¡§¹âÎï¿Í»²100mg¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹60mg¡Ë
or
320mg¡ÊÃí¡§¹âÎï¿Í»²200mg¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹120mg¡Ë
¤òñ²óÆâÉþ¤·¡¢60ʬ¸å¤ÎÀ¸Íý³ØŪ¸ú²Ì¤òɾ²Á¤·¤Æ¤¤¤Þ¤¹¡£

¤½¤Î·ë²Ì°ÂÁ´À­¤¬¾ÚÌÀ¤µ¤ì¡¢¤Þ¤¿·ì°µ¤äÌ®Çï¡¢·ì¾®ÈĶŽ¸¡¢ÈéÉæÌÓºÙ·ì´É¤Ç¤ÎÀÖ·ìµå®Å٤βþÁ±¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¡£

¤½¤Î¸ú²Ì¤Ï320mgÆâÉþ·²¤ÎÊý¤¬¹â¤¤¤â¤Î¤Ç¤·¤¿¡£


3.2.2 Gincosan¤È¥×¥é¥»¥Ü¤Ç¤ÎĹ´ü/½é´ü¸ú²Ì¤ÎÈæ³Ó
1997ǯKiesewetter¤é¤ÏGINCOSAN¤Î¿Í¤Î¹ÔÆ°¤ËÂФ¹¤ë¸ú²Ì¤òÄ´ºº¤·¤Æ¤¤¤Þ¤¹¡£

43-72ºÐ¤Î85¿Í¤ÎÈ︳¼Ô¤òÂоݤËÆó½ÅÌÕÌÜ¥é¥ó¥À¥à²½¥×¥é¥»¥Ü¥³¥ó¥È¥í¡¼¥ë¸¦µæ¤Î·Á¤Ç¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£

ºÇ½é¤Î4½µ´Ö¥×¥é¥»¥Ü¤òÆâÉþ¡¢¤½¤Î¸å¤Î8½µ´ÖGincosan¤òÆâÉþ¤·¤Æ¤â¤é¤¤¡¢4½µÌÜ»þÅÀ¤È8½µÌÜ»þÅÀ¤Ç¤ÎÎ×¾²É¾²Á¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£

¤³¤ÎÏÀʸ¤Ç¤Ï¡Ö4½µÌܡסÖ8½µÌܡפȤ¤¤¦¤Î¤¬¡¢Gincosan¤òÆâÉþ³«»Ï¤·¤Æ¤«¤é¡Ö4½µ¡×¡Ö8½µ¡×¤Ê¤Î¤«¡¢¥®¥ó¥³¥µ¥ó¤ÎÆâÉþ¤¹¤Ù¤Æ¤¬½ªÎ»¤·¤Æ¤«¤é¡Ö4½µ¡×¡Ö8½µ¡×¤Ê¤Î¤«½ñ¤«¤ì¤Æ¤¤¤Ê¤¤¤¿¤á¡¢´°Á´¤Ë¡ÖĹ´ü¸ú²Ì¡×¤È¸À¤¤Àڤ뤳¤È¤Ï¤Ç¤­¤Ê¤¤¤À¤í¤¦¡£

¤³¤Î¤è¤¦¤ÊÌäÂêÅÀ¤Ï¤¢¤ë¤¬¡¢Gincosan¤Ï¿Í¤Î¹ÔÆ°¤ËÊѲ½¤ò¤â¤¿¤é¤·¤¿¤è¤¦¤Ç¤¹¡£

ÆäË8½µÌܤÎɾ²Á¤Ç½¸ÃæÎϤÈ˺¤ì¤Ã¤Ý¤µ¤ÎÅÀ¤Ç²þÁ±¤¬Ç§¤á¤é¤ì¤Æ¤¤¤Þ¤¹¡£


3.2.3 Gincosan¤ÎÍÑÎ̤ˤè¤ë½é´ü/Ĺ´ü¸ú²Ì¤Ë½ÅÅÀ¤òÃÖ¤¤¤¿¸¦µæ
1997ǯ¡¢Wesnes¤é¤ÏÊ¿¶ÑǯÎð54ºÐ¤Î64¿Í¤ÎÈ︳¼Ô¤òÂоݤË80mg, 160mg, 320mg¤Î3¤Ä¤ÎÍÑÎ̤ò¤½¤ì²¶ÆâÉþ¤·¤Æ¤â¤é¤¦¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£

2¤Ä¤ÎǧÃιàÌܡʵ­²±ÎϤÈÃí°ÕÎϡˤËÂФ¹¤ëɾ²Á¤ÈÈ︡¼Ô¤Îµ¤Ê¬¤ËÂФ¹¤ëɾ²Á¤ª¤è¤Ó¾ðÊó½èÍý¥¹¥Ô¡¼¥É(Vienna Determination Test)¤È±¿Æ°»þºÇÂç¿´Çï¿ô¤Îɾ²Á¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£

ɾ²Á¤ÏÆâÉþ1ÆüÌÜ¡¢30ÆüÌÜ¡¢90ÆüÌܤǹԤ¤¤Þ¤·¤¿¡£

160mgÆâÉþ·²¤ª¤è¤Ó320mgÆâÉþ·²¤Ç¤Ïµ­²±ÎϤβþÁ±¤¬Ç§¤á¤é¤ì¤¿°ìÊý¡¢80mgÆâÉþ·²¤Ç¤ÏÍ­¸úÀ­¤Ïǧ¤á¤é¤ì¤Þ¤»¤ó¤Ç¤·¤¿¡£

È¿ÂФË80mgÆâÉþ·²¤Ç¤ÏºÇÂçÉé²Ù»þ¿´Çï¿ô¤Î¾å¾º¤¬ÍÞ¤¨¤é¤ì¡¢È︳¼Ô¤Î¿ÈÂΤËÂФ·¤Æ¤ÏÍ­±×¤Ê¸ú²Ì¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¡£

¾ðÊó½èÍý¥¹¥Ô¡¼¥É¤Ç¤ÏÍ­°Õ¤ÊÊѲ½¤Ïǧ¤á¤é¤ì¤Þ¤»¤ó¤Ç¤·¤¿¡£¡Ê°Ê²¼¾Êά¡Ë


3.2.4 Ĺ´ü¡¢Ä¹´ü/½é´ü¤Ë¤ª¤±¤ëÍÑÎ̤ˤè¤ëGincosan¤Î¸ú²Ì
´ØÏ¢¤·¤¿4¤Ä¤Î¸¦µæ¤¬¤Ê¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

Wesnes¤é¤Ï2000ǯ256¿Í¤Î·ò¾ï¿Í¤òÂоݤË160mg 1Æü2²ó¡¢¤â¤·¤¯¤Ï320mg 1Æü1²óÆâÉþ¤·¤Æ¤â¤é¤¤¡¢Æó½ÅÌÕÌܥץ饻¥Ü¥³¥ó¥È¥í¡¼¥ë¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£

¤³¤Î¥×¥í¥È¥³¡¼¥ë¤Ï¤«¤Ê¤ê¤·¤Ã¤«¤ê¤·¤¿¤â¤Î¤Ç16½µ¤Ë¤ï¤¿¤Ã¤Æ¹Ô¤ï¤ì¤Æ¤¤¤Þ¤¹¡£

¤¹¤Ù¤Æ¤ÎÈ︳¼Ô¤Ë2½µ´Ö¥×¥é¥»¥Ü¤òÆâÉþ¤·¤Æ¤â¤é¤¤¡¢¤½¤Î¸å12½µ´ÖGincosan¤ò¡¢¤µ¤é¤Ë2½µ´Ö¤Îwash-out´ü´Ö¤òÀߤ±¤Æ¤¤¤Þ¤¹¡£

ɾ²Á¤Ï¥×¥é¥»¥ÜÆâÉþÁ°¸å¡¢GincosanÆâÉþ³«»Ï¸å4½µ¡¢8½µ¡¢12½µ¡¢ÆâÉþ½ªÎ»¸å2½µÌܤǹԤï¤ì¤Æ¤¤¤Þ¤¹¡£

1) µ­²±¤ÎÀµ³Î¤µ¡¡2) µ­²±¤ÎÁᤵ¡¡3) ½¸ÃæÎÏ¡¡4) ½¸ÃæÎϤλý³¤òɾ²Á¹àÌܤȤ·¤Æ¤¤¤Þ¤¹¡£

¶½Ì£¿¼¤¤·ë²Ì¤È¤·¤Æ¡¢Gincosan¤òÆâÉþ¤¹¤ë¤ÈÆâÉþ¤ò4,8,12,14½µ¤Îɾ²Á»þÅÀ¤¹¤Ù¤Æ¤Çµ­²±ÎϤËÍ­°Õ¤Ê²þÁ±¤¬Ç§¤á¤é¤ì¤Æ¤¤¤Þ¤¹¡£

¤Ä¤Þ¤ê¡¢¤½¤Î¸ú²Ì¤ÏÆâÉþÃæ»ß¸å2½µ´Ö»ý³¤·¤¿¤Î¤Ç¤¹¡£

¤³¤Î¤³¤È¤Ë¤è¤ê¡¢Gincosan¤Ïµ­²±ÎϤËĹ´üŪ¸ú²Ì¤¬¤¢¤ë¤³¤È¤¬³Î¤«¤á¤é¤ì¤¿¤Î¤Ç¤¹¡£¡Ê°Ê²¼¾Êά¡Ë


3.2.5 Gincosan¤È¥×¥é¥»¥Ü¤ÎÆâÉþ½é´ü¤Î¸ú²Ì¤ÎÈæ³Ó
û´ü¸ú²Ì¤Ë¤Ä¤¤¤Æ¤Ï¡¢Kennedy¤é¤¬2001ǯÆó½ÅÌÕÌܥץ饻¥Ü¥³¥ó¥È¥í¡¼¥ë»î¸³¤Î·Á¤Ç¸¦µæÊó¹ð¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£

Ê¿¶ÑǯÎð20.6ºÐ¤Î20¿Í¤Î·ò¾ï¿Í¤òÂоݤË7Æü´Ö¤Îwash-out´ü´Ö¤òÀߤ±¤¿¤Î¤Á¡¢320mg, 640mg, 960mg¤òÆâÉþ¤·¤Æ¤â¤é¤Ã¤Æ¤¤¤Þ¤¹¡£

¤½¤·¤Æ¡¢ÆâÉþÁ°¤ÈÆâÉþ¸å1,2.5,4,6»þ´Ö»þÅÀ¤Ç¤Îɾ²Á¤ò¹Ô¤¤¤Þ¤·¤¿¡£

6¹àÌÜa) µ­²±¤Î¼Á¡¡b) Æ󼡵­²±¡¡c) ¥ï¡¼¥­¥ó¥°¥á¥â¥ê¡¼¡¡d) µ­²±¥¹¥Ô¡¼¥É¡¡e) Ãí°ÕÎϤÎÁᤵ¡¡f) Ãí°ÕÎϤÎÀµ³Î¤µ ¤Ë¤Ä¤¤¤Æɾ²Á¤·¤Æ¤¤¤Þ¤¹¡£

960mgÆâÉþ·²¤Ç¤Ï¡¢ÆâÉþ¸å1»þ´Ö¤È6»þ´Ö»þÅÀ¤Ç¤Îµ­²±ÎϤμÁ¤Î²þÁ±¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¡£

¤³¤Î¸¦µæ¤Ç¤Ïµ­²±ÎϤËÂФ·¤ÆÍ­±×¤Ê¸ú²Ì¤¬Ç§¤á¤é¤ì¡¢Ãí°ÕÎϤؤθú²Ì¤Ïǧ¤á¤é¤ì¤Þ¤»¤ó¤Ç¤·¤¿¡£


3.2.6 Gincosan¡¢¥®¥ó¥³¡¢¹âÎï¿Í»²¡¢¥×¥é¥»¥Ü´Ö¤Ç¤Îû´ü¸ú²Ì¤ÎÈæ³Ó
Kennedy¤é¤Î2¤ÄÌܤ覵æ¤ÏGincosan¤È¤½¤Î¹½À®Êª¼ÁñÂΡ¢¡Ê¥®¥ó¥³¡¢¹âÎï¿Í»²¡Ë¤Ç¤Î¸ú²Ì¤ÎÈæ³Ó¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£

Ê¿¶ÑǯÎð21ºÐ¤Î·ò¾ï¿Í20¿Í¤òÂоݤË7Æü´Ö¤Îwash-out´ü´Ö¤òÀߤ±¤¿¤Î¤Á¡¢¥é¥ó¥À¥à¤Ë¥®¥ó¥³360mg¡¢¿Í»²400mg¡¢Gincosan960m¡¢¥×¥é¥»¥Ü¤òÆâÉþ¤·¤Æ¤â¤é¤¤¤Þ¤·¤¿¡£

ÆâÉþÁ°¡¢ÆâÉþ¸å1,2.5,4,6»þ´Ö¤Î»þÅÀ¤Ç3.2.5¤Î¸¦µæ¤Çɾ²Á¤·¤¿6¹àÌܤˤĤ¤¤ÆÄ´ºº¤·¤Þ¤·¤¿¡£

6¹àÌܤÎɾ²Á·ë²Ì¤ò¸«¤ë¤È¡¢Gincosan960mg¡ÊÃí¡§6¥«¥×¥»¥ë¡ËÆâÉþ·²¤Ç¤Ï¡Èµ­²±¤Î¼Á¡É¤Î²þÁ±¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¡£

²Ã¤¨¤Æ¡¢¤½¤Î¸ú²Ì¤Ï2¼¡µ­²±¤ÎÀ®ÀӤξ徺¤Ë¤è¤ê¤â¤¿¤é¤ì¤ë¤â¤Î¤Ç¤¢¤ë¤³¤È¤¬¤ï¤«¤Ã¤¿¤Î¤Ç¤¹¡£¡ÊÅÓÃæ¾Êά¡Ë

º£²ó¤Î¸¦µæ¤ÇGincosan¤È¤½¤Î¹½À®Êª¼ÁñÂΤȤÎÈæ³Ó¤ò¤·¤¿¤³¤È¤Ç¡¢¤½¤ÎÁê¾è¸ú²Ì¤Ë¤Ä¤¤¤Æɾ²Á¤¹¤ë¤³¤È¤¬¤Ç¤­¤Þ¤·¤¿¡£

µ­²±¤Î¼Á¤Ë´Ø¤·¤Æ¤Ï¡¢¥®¥ó¥³¡¢¹âÎï¿Í»²Ã±ÂΤǤ¢¤Ã¤Æ¤âµ­²±¤Î¼Á¤Î²þÁ±¤Ï¸«¹þ¤á¤ë¤â¤Î¤Î¡¢¸ú²Ì¤òȯ´ø¤¹¤ë»þ´Ö¤Ï¤½¤ì¤¾¤ì°Û¤Ê¤Ã¤Æ¤¤¤Þ¤·¤¿¡£¡Ê¥®¥ó¥³¤ÏÆâÉþ¸åÌó6»þ´Ö¡¢¹âÎï¿Í»²¤ÏÆâÉþ¸åÌó4»þ´Ö¡Ë

¤³¤Î·ë²Ì¤Ë¤è¤ê¡¢¥®¥ó¥³¤È¹âÎï¿Í»²¤òÁȤ߹ç¤ï¤»¤ë¤³¤È¤Ë¤è¤ê¡¢µ­²±¤Î¼Á¤Î²þÁ±¤¬¤è¤ê¥Ñ¥ï¥Õ¥ë¤Ë¤Ï¤Ã¤­¤ê¤È¤·¤¿¤â¤Î¤Ë¤Ê¤ë²ÄǽÀ­¤¬¤¢¤ê¡¢¤µ¤é¤Ë¸ú²Ìȯ¸½»þ´Ö¤âÁᤤ¤â¤Î¤Ë¤Ê¤ë¡ÊÆâÉþ¸å60ʬ¡Ë²ÄǽÀ­¤¬¼¨º¶¤µ¤ì¤Þ¤·¤¿¡£


3.2.7 û´ü¤ÎÍÑḬ̂͸À­¸ú²Ì¤Ë¤ª¤±¤ëGincosan¡¢¥®¥ó¥³¡¢¹âÎï¿Í»²¡¢¥×¥é¥»¥Ü¤ÎÈæ³Ó
Scoley¡¢Kennedy¤é¤Î3¤ÄÌܤ覵æ¤Ç¤Ï3.2.6¤Î¸¦µæ¤ò¤µ¤é¤Ë¿Ê¤á¡¢ÍÑÎ̤ˤè¤ë¸ú²Ì¤Î°ã¤¤¤òÌÀ¤é¤«¤Ë¤¹¤ë¤¿¤á¡¢3¤Ä¤Î¸¦µæ¤¬¹Ô¤ï¤ì¤Æ¤¤¤Þ¤¹¡£

¤¤¤º¤ì¤âÆó½ÅÌÕÌܥץ饻¥Ü¥³¥ó¥È¥í¡¼¥ë¸òºµ»î¸³¤Ç¥®¥ó¥³¤ò120mg¡¢240mg¡¢360mg¡¢¹âÎï¿Í»²¤ò200mg¡¢400mg¡¢600mg¡¢¥®¥ó¥³¥µ¥ó¤ò320mg¡¢640mg¡¢960mgÆâÉþ¤·¤Æ¤â¤é¤Ã¤Æ¤¤¤Þ¤¹¡£

·ë²Ì¥®¥ó¥³¥µ¥ó¤Ç¤ÏÌÀ³Î¤ËÍÑḬ̂͸À­¤Î¸ú²Ì¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¡£¡Ê°Ê²¼¾Êά¡Ë


3.2.8 ¾Êά


Discussion
º£²ó½¸¤á¤¿8¤Ä¤Î¸¦µæ·ë²Ì¤Î¸¡Æ¤¤Ë¤è¤ê¿Í»²¤È¥®¥ó¥³¤Î°û¤ß¹ç¤ï¤»¤ÏǧÃε¡Ç½¤Î²þÁ±¤Ë¤è¤ê¸ú²Ì¤¬¤¢¤ë¤³¤È¤¬¤Ï¤Ã¤­¤ê¤È¤·¤Þ¤·¤¿¡£

¤³¤Î¸ú²Ì¤Ï·ò¾ï¿Í¤Ç¤âǧ¤á¤é¤ì¡¢ÆâÉþ¸å60ʬÄøÅ٤Ǹú²Ì¤¬È¯¸½¤·¡¢ÆâÉþÃæ»ß¸å¤â14Æü´ÖÄøÅÙ»ý³¤¹¤ë¤³¤È¤¬¤ï¤«¤ê¤Þ¤·¤¿¡£¡Ê°Ê²¼¾Êά¡Ë
gincosan

¿·switch %282%29


¥­¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á¤Ï¡¢¥¢¥Þ¥¾¥ó¡¢³ÚÅ·¤Ç¤âÆþ¼ê¤Ç¤­¤Þ¤¹¡£

¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ë¤Ä¤¤¤Æ¡¢¶½Ì£¿¼¤¤ÏÀʸ¤òÌõ¤·¤Þ¤·¤¿¤Î¤Ç¤´¾Ò²ð¤·¤Þ¤¹¡£

¡Ö·ò¹¯¤Ê¼ãǯÈ︳¼Ô¤òÂоݤȤ·¤¿¥®¥ó¥³¤òû´üÆâÉþ¤·¤¿ºÝ¤ÎǧÃε¡Ç½¤ËÂФ¹¤ëÍÑḬ̂͸À­¸ú²Ì¤Î¸¡Æ¤¡×

The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers.

PMID:11026748
https://www.ncbi.nlm.nih.gov/pubmed/?term=11026748


Abstract
Rationale:¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¡Ê¥®¥ó¥³¡Ë¤òĹ´ü¤ËÆâÉþ¤¹¤ë¤³¤È¤Ë¤è¤ê¡¢Ç§Ãε¡Ç½¤¬²þÁ±¤¹¤ë¤³¤È¤¬¤ï¤«¤Ã¤Æ¤­¤Æ¤¤¤Þ¤¹¡£

¤·¤«¤·¡¢¥®¥ó¥³¤Îû´üŪºîÍѤˤĤ¤¤Æ¤Ï¤Ï¤Ã¤­¤ê¤È¤ï¤«¤Ã¤Æ¤¤¤ë¤³¤È¤Ï¾¯¤Ê¤¤¾õÂ֤Ǥ·¤¿¡£

ºÇ¶á¤Î¸¦µæ¤Ë¤è¤ê¡¢C£ÄR(Cognitive Drug Research)¤Ë¤è¤ê¬Äꤵ¤ì¤¿4¤Ä¤ÎǧÃιàÌÜ(Ãí°ÕÎϤήÅÙ¡¢Ãí°ÕÎϤÎÀµ³Î¤µ¡¢µ­²±¤Î®ÅÙ¡¢µ­²±¤ÎÀµ³Î¤µ)¤¬Ç§Ãε¡Ç½¤ÎÊѲ½¤ò¬Äꤹ¤ë¤Î¤ËÍ­ÍѤǤ¢¤ë¤³¤È¤¬¤ï¤«¤Ã¤Æ¤­¤Þ¤·¤¿¡£


Objective:º£²ó¤Î¸¦µæ¤Ç¤Ï¥®¥ó¥³¤òCDR4¹àÌܤËÌÀ³Î¤Ê¸ú²Ì¤ò¤â¤¿¤é¤¹¤«¤É¤¦¤«¤òɾ²Á¤·¤Þ¤·¤¿¡£


Method:¤³¤Î¸¦µæ¤ÏÆó½ÅÌÕÌܥץ饻¥Ü¥³¥ó¥È¥í¡¼¥ë¸òºµ»î¸³¤Î·Á¤Ç¹Ô¤¤¤Þ¤·¤¿¡£

20¿Í¤ÎÈ︳¼Ô¤òÂоݤ˥®¥ó¥³Ãê½Ðʪ120mg,240mg,360mg¤â¤·¤¯¤Ï¥×¥é¥»¥Ü¤òÆâÉþ¤·¤Æ¤â¤é¤¤¤Þ¤·¤¿¡£

ǧÃε¡Ç½¤òCDR¥³¥ó¥Ô¥å¡¼¥¿¥Æ¥¹¥È¤Ë¤è¤êÆâÉþÁ°¡¢ÆâÉþ¸å1,2.5,4,6»þ´Ö¤Ç¬Äꤷ¡¢¤½¤ì¤Ë¤è¤êǧÃε¡Ç½¤Î4¹àÌܤˤĤ¤¤Æɾ²Á¤·¤Þ¤·¤¿¡£


Results:¥×¥é¥»¥Ü·²¤ÈÈæ³Ó¤·¤Æ¥®¥ó¥³¤òÆâÉþ¤¹¤ë¤È¿¤¯¤ÎÍ­°Õ¤ÊÊѲ½¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¡£

¤½¤ì¤é¤ÎÃæ¤ÇºÇ¤â¤Ï¤Ã¤­¤ê¤È¤·¤¿¤â¤Î¤¬¡¢ÍÑḬ̂͸À­¤ÎÃí°ÕÎϤήÅ٤βþÁ±¤Ç¤·¤¿¡£

240mg,360mgÆâÉþ·²¤É¤Á¤é¤â¤ÇÍ­°Õ¤Ê²þÁ±¤¬Ç§¤á¤é¤ì¡¢ÆâÉþ2.5»þ´Ö¸å¤ÇºÇ¤â¤Ï¤Ã¤­¤ê¤·¤¿¸ú²Ì¤¬¤¢¤ê¡¢ÆâÉþ6»þ´Ö¸å¤Ç¤â¤½¤Î¸ú²Ì¤Ï»ý³¤·¤Æ¤¤¤Þ¤·¤¿¡£


Conclusion:º£²ó¤Î¸¦µæ¤Ç·ò¹¯¤Ê¼ã¤¤È︳¼Ô¤òÂоݤȤ·¤¿¸¦µæ¤Ç¥®¥ó¥³ÆâÉþ¤Ë¤è¤êÃí°ÕÎϤλý³Ū¤Ê²þÁ±¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¡£

¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦¡¦
°Ê¾å°úÍѤò½ªÎ»¡£

¤ª´«¤á¤Î¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¡¢

¥­¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH¡¢¤« ¥¯¡¼¥ë¥¹¥¦¥£¥Ã¥ÁCOOL SWITCH ¡£

2¥«¥×¥»¥ë¤Ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤¬120­Ó¡£

²Ã¤¨¤Æ¡¢Ç¾µ¡Ç½¤Î¤¿¤á¤Î¹âÎï¿Í»²¡ÊCOOL SWITCH ¤Ï¥¢¥á¥ê¥«¿Í»²¡Ë¡¢¥Ð¥³¥Ñ¡¢¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤âÇ۹礵¤ì¤Æ¤¤¤Þ¤¹¡£

¤³¤ì¤é¤ÎÁȤ߹ç¤ï¤»¤Ë¤Ï¡¢Îɹ¥¤ÊƯ¤­¤¬´üÂԤǤ­¤ë¤«¤é¤Ç¤¹¡£

¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¹âÎï¿Í»²¤ÎƱ»þÀݼè¤Ï¡¢µ­²±ÎÏ¡¢½¸ÃæÎÏ¡¢Ãí°ÕÎϤؤΥµ¥Ý¡¼¥È¤¬´üÂԤǤ­¤Þ¤¹¡£

PMID: 30729756
https://www.ncbi.nlm.nih.gov/pubmed/?term=30729756


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¥¢¥á¥ê¥«¿Í»²¤ÎÁȤ߹ç¤ï¤»¤Ï¡¢ADHD¤Î²þÁ±¤¬´üÂԤǤ­¤ë

PMID:11394191
https://www.ncbi.nlm.nih.gov/pubmed/?term=11394191

¤³¤ì¤Ï¡¢¹âÎï¿Í»²¤â¥¢¥á¥ê¥«¿Í»²¤ÈƱÍͤγèÀ­À®Ê¬¤ò»ý¤Ä¤Î¤Ç¡¢¹âÎï¿Í»²¤È¥¤¥Á¥ç¥¦ÍÕ¤âADHD¤ËÎɹ¥¤Ê·ë²Ì¤ò¤â¤¿¤é¤¹¤³¤È¤¬´üÂԤǤ­¤Þ¤¹¡£


¤Þ¤¿¡¢¥¢¥á¥ê¥«¿Í»²¤Ï¡¢¥ï¡¼¥­¥ó¥°¥á¥â¥ê¡¼¤Î¶¯²½¤¬´üÂԤǤ­¤Þ¤¹¡£

PMID:2952762
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952762/



²Ã¤¨¤Æ¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤ÎÁȤ߹ç¤ï¤»¤Ï¡¢

¡ÖÃí°ÕÎϤΥ¹¥Ô¡¼¥É¡×

¡ÖÃí°ÕÎϤÎÀµ³ÎÀ­¡×

¡Öµ­²±ÎϤΥ¹¥Ô¡¼¥É¡×

¡Öµ­²±¤ÎÀµ³ÎÀ­¡×

¡ÖÆ󼡵­²±¡×

¡Ö¥ï¡¼¥­¥ó¥°¥á¥â¥ê¡¼¡×

¤ËÎɹ¥¤Ê¤è¤¦¤Ç¤¹¡£

http://livedoor.blogcms.jp/blog/taddy_/article/edit?id=51897998


¥Ð¥³¥Ñ¥¨¥­¥¹¤ÎǧÃε¡Ç½¤Ø¤Î¥µ¥Ý¡¼¥ÈÎϤ⤢¤Ê¤É¤ì¤Þ¤»¤ó¡£

http://livedoor.blogcms.jp/blog/taddy_/article/edit?id=52003735



µ­²±ÎÏ¡¢½¸ÃæÎÏ¡¢Ãí°ÕÎϤò½õ¤±¤¿¤¤Êý¤Ï¡¢¥­¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á¡¢¥¯¡¼¥ë¥¹¥¦¥£¥Ã¥Á¤ò¸¡Æ¤¤µ¤ì¤Æ¤Ï¤¤¤«¤¬¤Ç¤·¤ç¤¦¤«¡£

¥¢¥Þ¥¾¥ó¡¢³ÚÅ·¤Ç¤âÆþ¼ê¤Ç¤­¤Þ¤¹¡£

¢§¥¢¥Þ¥¾¥ó
https://www.amazon.co.jp/
¢§³ÚÅ·
https://www.rakuten.co.jp/

¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤¬Ç¾¤ËÎɤ¤Íýͳ¤Ï¡¢·ìή¤òÁý¤ä¤¹¤«¤é¤À¤±¤Ç¤Ï¤Ê¤¤¤è¤¦¤À¡£



Æî¥ß¥·¥·¥Ã¥ÔÂç³Ø¤Î J. V. Smith »á¡¢ Y. Luo »á¤Ë¤è¤ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Î¥ì¥Ó¥å¡¼¤ò¤´¾Ò²ð¤·¤Þ¤·¤ç¤¦¡£


¡Ö¥®¥ó¥³ ¥Ó¥í¥Ð ¥¨¥¯¥¹¥È¥é¥¯¥È ( ¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹ ) ¤Îʬ»Ò³ØŪ¥á¥«¥Ë¥º¥à¤Ë´Ø¤¹¤ë¸¦µæ¡×
Studies on molecular mechanisms of Ginkgo biloba extract Appl Microbiol Biotechnol (2004) 64: 465¡Ý472 J. V. Smith . Y. Luo




¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ë¤Ï£²¤Ä¤ÎÀ®Ê¬¤¬¤¢¤ê¡¢¤½¤ì¤é¤¬¥æ¥Ë¡¼¥¯¤ÊÌôÍýºîÍѤò¤â¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¤È¤³¤í¤«¤é¤³¤Î¥ì¥Ó¥å¡¼¤Ï»Ï¤Þ¤ë¡£


1)¥Æ¥ó¥Ú¥ë


2)¥Õ¥é¥Ü¥Î¥¤¥É



1)¥Æ¥ë¥Ú¥ó¤Ï¼¡¤ËʬÎव¤ì¤ë¡£


a)¥®¥ó¥³¥é¥¤¥É A¡¢B¡¢C¡¢J¡¢M


b)¥Ó¥í¥Ð¥é¥¤¥É



a)¥®¥ó¥³¥é¥¤¥É¤Î¸ú²Ì


¡Ö ¥®¥ó¥³¥é¥¤¥É¤Ï·ì¾®ÈijèÀ­²½°ø»Ò (PAF) ¤Î¥¢¥ó¥¿¥´¥Ë¥¹¥È¤Ç¡¢·ì¾®ÈijèÀ­²½¤ª¤è¤Ó¶Å½¸¤òÁ˳²¤¹¤ë¡£¤½¤ì¤Ë¤è¤Ã¤Æ·ì±Õ½Û´Ä¤ò²þÁ±¤¹¤ë ¡×¡Ê1¡Ë


¥¢¥ó¥¿¥´¥Ë¥¹¥È¤È¤Ï¤¢¤ëºîÍѤòÁ˳²¤¹¤ëʪ¼Á (Ùɹ³Êª¼Á) ¡£


¤Ä¤Þ¤ê¥®¥ó¥³¥é¥¤¥É¤Ï·ìÀò¤Î·ÁÀ®¤òËɤ°¤³¤È¤¬´üÂԤǤ­¤ë¡£



2)¥Õ¥é¥Ü¥Î¥¤¥É¤Î¸ú²Ì


¥Õ¥é¥Ü¥Î¥¤¥É¤Ï¹³»À²½ºîÍѤòȯ´ø¤¹¤ë¡£

¡Ö ¥Õ¥é¥Ü¥Î¥¤¥É¤Ï˧¹á´Ä¤ª¤è¤ÓÆó½Å·ë¹ç¤Ë¤è¤Ã¤Æ¹½À®¤µ¤ì¤Æ¤¤¤ë¡£¤½¤ì¤Ë¤è¤Ã¤Æ¡¢¥Ò¥É¥í¥­¥·¥ë¥é¥¸¥«¥ë¤Ë¤è¤êÈ¿±þ¤·¤ä¤¹¤¯¡¢Ä¾ÀÜŪ¥¹¥«¥Ù¥ó¥¸ºîÍѤòÍ­¤¹¤ë ¡×(2)


¥Ò¥É¥í¥­¥·¥ë¥é¥¸¥«¥ë¤Ï¥Õ¥ê¡¼¥é¥¸¥«¥ë¡£


¥Ò¥É¥í¥­¥·¥ë¥é¥¸¥«¥ë¤Ï¾¤Îʪ¼Á¤ÈÈ¿±þ¤·¤ä¤¹¤¯¡¢Åü¡¢»é¼Á¡¢¥¿¥ó¥Ñ¥¯¡¢£Ä£Î£Á¤ò½ý¤Ä¤±¤ë¡£


¥Ë¥å¡¼¥í¥ó¤ò·ÁÀ®¤¹¤ëʪ¼Á¤Ç¤¢¤ëÉÔË°Ï»éËûÀ¤ËÂФ·¤Æ¤â¡¢¤³¤Î¥é¥¸¥«¥ë¤¬»À²½¥À¥á¡¼¥¸¤òÍ¿¤¨¤ë¡£


¥Õ¥é¥Ü¥Î¥¤¥É¤Ï¤Ä¤Þ¤ê¥Ë¥å¡¼¥í¥ó¤ò»À²½¤«¤é¼é¤ë¤³¤È¤¬´üÂԤǤ­¤ë¡£


¤µ¤é¤Ë


¡Ö SOD ( superoxide dismutase ) ¤Î¤è¤¦¤Ê¹³»À²½¥¿¥ó¥Ñ¥¯¼Á¤Îȯ¸½¡¢¥°¥ë¥¿¥Á¥ª¥ó¤Î¤è¤¦¤Ê¹³»À²½Âå¼Õʪ¼Á¤òÁý²Ã¤µ¤»¤ë ¡×(3)¡¨(4)


SOD¤È¤ÏÁ°½Ð¤Î¥Ò¥É¥í¥­¥·¥ë¥é¥¸¥«¥ë¤ò̵³²²½¤¹¤ë¹ÚÁǤΤ³¤È¡£


¤È¤³¤í¤¬SOD¤Ï²ÃÎð¤Ëȼ¤¤¸º¾¯¤·¤Æ¤·¤Þ¤¦¡£


¤·¤«¤·¥Õ¥é¥Ü¥Î¥¤¥É¤ÏSOD¤òÁý²Ã¤µ¤»¤ë¡£




¡Ö ¥Õ¥é¥Ü¥Î¥¤¥É¾å¤Î¿å»À´ð¤Ï prooxidant transitional metal ions (Î㤨¤ÐFe2+) ¤È·ë¹ç¤·¤Æ¥­¥ì¡¼¥È´Ä¤òºî¤ë ¡×(3)


¡Ö ¤½¤ì¤Ë¤è¤ê¿·¤¿¤Ê¥Ò¥É¥í¥­¥·¥é¥¸¥«¥ë¤ÎÀ¸À®¤òÁ˳²¤¹¤ë ¡×(2)¡¨(5)


Å´¤Ï»¬¤Ó¤ä¤¹¤¤¡£


¤½¤ì¤ÏÀ¸ÂÎÆâ¤ÎÅ´¤Ç¤âƱ¤¸¤Ç¤¹¡£


¾åµ­¤Ï¡¢¥Õ¥é¥Ü¥Î¥¤¥É¤¬Å´¤ÈÈ¿±þ¤·¤Æ»À²½¤òËɤ°¤È¤¤¤¦Êó¹ð¡£






¤½¤ì¤Ç¤Ï¤½¤ì¤éÀ®Ê¬¤ò´Þ¤à¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Î¼çÍפʸú²Ì¤Ë¤Ä¤¤¤Æ¡£



£± ¥Õ¥ê¡¼¥é¥¸¥«¥ë¡¢»À²½¥¹¥È¥ì¥¹¤Ë¤Ä¤¤¤Æ


¡Ö ¥Õ¥ê¡¼¥é¥¸¥«¥ë¥¹¥«¥Ù¥ó¥¸¥ã¡¼³èÀ­²½ºîÍѤò¤â¤Ã¤Æ¤¤¤ë ¡×

¡Ö ROS ( reactive oxygen species ) ¤ÎÁÈ¿¥ÆâÇ»ÅÙ¤ò¸º¾¯¤µ¤»¤ë ¡×(6)¡¨(7)¡¨(8)


ROS ( ³èÀ­»ÀÁǼï ) ¤È¤Ï¥Õ¥ê¡¼¥é¥¸¥«¥ë¡¢³èÀ­»ÀÁǤÎÁí¾Î¡£


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¤½¤ì¤ò¸º¤é¤¹¤È¤¤¤¦¡¢¤³¤ì¤Ï¹³»À²½ºîÍѤˤĤ¤¤Æ¤ÎÊó¹ð¡£



¡Ö Ëì»é¼Á²á»À²½È¿±þ¤òÍÞÀ©¤¹¤ë ¡×(6)


Ëì»é¼Á²á»À²½È¿±þ¤È¤Ï¡¢»é¼Á¤Î»À²½¤¬Ï¢º¿¤¹¤ë¤È¤¤¤¦¸½¾Ý¤Î¤³¤È¡£


¤¢¤ë¤­¤Ã¤«¤±¤Ç¿åÁǤò°ú¤­È´¤«¤ì¤¿»é¼Á¤Ï¡¢¥Õ¥ê¡¼¥é¥¸¥«¥ë¤È²½¤¹¡£


¤½¤ì¤¬¤³¤ÎÏ¢º¿¤Î»Ï¤Þ¤ê¡£


¥é¥¸¥«¥ë²½¤·¤¿»é¼Á¤Ï¾¤Îʪ¼Á¤«¤éÅŻҤòÃ¥¤¤¥é¥¸¥«¥ë¤òÁý¤ä¤·¤Æ¤æ¤¯¡£


Áý¤¨¤¿¥é¥¸¥«¥ë¤Ï·òÁ´¤Ê»é¼Á¤Î¿åÁǤò¤Ä¤®¤Ä¤®°ú¤­¤Ì¤¯¡£


¤È¤¤¤¦¤è¤¦¤Ë¡¢Ëì»é¼Á²á»À²½È¿±þ¤È¤Ï¡¢¤¤¤ï¤Ð»é¼Á¥¾¥ó¥Ó²½¸½¾Ý¡£


¤½¤·¤Æ¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¤½¤ÎÏ¢º¿È¿±þ¤òÍÞÀ©¤¹¤ëƯ¤­¤òÍ­¤¹¤ë¡£


¤Á¤Ê¤ß¤Ë¡¢


¥Ó¥¿¥ß¥óE¤â»é¼Á¥é¥¸¥«¥ë¤ò¸µ¤ËÌ᤹ʪ¼Á¡£


¤¿¤À¤·¡¢¥Ó¥¿¥ß¥ó£Å¤Î¥µ¥×¥ê¥á¥ó¥ÈÀݼè¤Ï¿Î̤ˤʤê¤ä¤¹¤¯ÃæÀ­»éËäò°ú¤­¾å¤²¤«¤Í¤Ê¤¤¤Î¤ÇÃí°Õ¤¬É¬Íס£


»é¼Á¤Î»À²½¤òËɤ°¤¿¤á¤Î¥µ¥×¥ê¥á¥ó¥È¤òÁª¤Ö¤Ê¤é¡¢¥Õ¥é¥Ü¥Î¥¤¥É¤¬Îɤ¤¤Ç¤·¤ç¤¦¡£




2 ¹³¥¹¥È¥ì¥¹ºîÍÑ


¡Ö Éû¿ÕÈé¼Á¤ÎPBR ( peripheral-type benzodiazepine receptor ) ¤Îȯ¸½¤ò¸º¤é¤¹ ¡×(6)


PBR¤È¤Ï¡¢Ëö¾¿·¿¥Ù¥ó¥¾¥¸¥¢¥¼¥Ô¥ó¼õÍÆÂΤΤ³¤È¤Ç¥³¥ë¥Á¥¾¡¼¥ë¤Î¹çÀ®¤Ë¤«¤«¤ï¤ë¼õÍÆÂΤΤ³¤È¡£


Éû¿ÕÈé¼Á¤Ë¿¤¯Â¸ºß¤·¤Æ¤¤¤ë¡£


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¥³¥ë¥Á¥¾¡¼¥ë¤ÎÀ¸»ºÎ̤ò¸º¤é¤¹¤è¤¦¤Ç¤¢¤ë¡£



¥³¥ë¥Á¥¾¡¼¥ë¤ÏÀ¸Â¸¤ËÉԲķç¤Ê¥Û¥ë¥â¥ó¤Ç¤Ï¤¢¤ë¤â¤Î¤Î¡¢À¸ÂΤËÍÍ¡¹¤Ê¾ã³²¤ò°ú¤­µ¯¤³¤¹¥Û¥ë¥â¥ó¤Ç¤â¤¢¤ë¡£


¤¿¤È¤¨¤Ð¥³¥ë¥Á¥¾¡¼¥ë¤ÎÂçÎÌȯÀ¸¡¢¤¹¤Ê¤ï¤Á¥¹¥È¥ì¥¹¤Ï¡¢³¤ÇϤò°Ñ½Ì¤µ¤»¤«¤Í¤Þ¤»¤ó¡£³¤ÇϤΥ˥塼¥í¥ó¤¬»àÌǤ·¤Æ¤¤¤Þ¤¹¡£


³¤ÇϤˤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤ¬Â¿¤¯¤¢¤ê¤Þ¤¹¡£


¡ÊÊ¢Éô¤â¿¤¯¤Æ¡¢¤À¤«¤é¥¹¥È¥ì¥¹¤Ï¤Ò¤È¤òÂÀ¤é¤»¤ë¡£¤¬¡¢¤½¤ì¤Ï¤Þ¤¿Ê̤ʵ¡²ñ¤Ë¡Ë


³¤ÇϤÏÀ¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤È¡Ö¸Æ¤Ó¤«¤±¤ë¡×´ï´±¤Ç¤¢¤ë¤¿¤á¡¢¥³¥ë¥Á¥¾¡¼¥ë¤ÎÌðÌ̤ËΩ¤Ä»ÅÁȤߤǤ¹¡£


¤·¤«¤·²á¾ê¤Ê¥³¥ë¥Á¥¾¡¼¥ë¤Ï¡ÊËýÀ­Åª¤Ê¥¹¥È¥ì¥¹¤Ï¡Ë³¤ÇϤΥ˥塼¥í¥ó¤ò¡Ö¶½Ê³ÆÇÀ­»à¡×¤Ø¤ÈÄɤ¤¹þ¤ß¤«¤Í¤Þ¤»¤ó¡£


¡Ö¶½Ê³ÆÇÀ­»à¡×¤È¤¤¤¦¸½¾Ý¤Ï¥Ë¥å¡¼¥í¥ó¤¬»àÌǤ¹¤ë»ÅÁȤߤΤҤȤĤǤ¹¡£


²á¾ê¤Ë»É·ã¤µ¤ì¤¿¥Ë¥å¡¼¥í¥óÆâ¤Ë¥«¥ë¥·¥¦¥à¥¤¥ª¥ó¤¬ÂçÎ̤ËήÆþ¤·¡¢¥Ë¥å¡¼¥í¥ó¤¬¶½Ê³¾õÂ֤Ȥʤꡢ²á³èÆ°¤òµ¯¤³¤·¡¢Èè¤ì²Ì¤Æ¡¢»àÌǤ¹¤ë¡¢¤È¤¤¤¦¸½¾Ý¡£


³¤ÇϤε¡Ç½¤Ë¤Ä¤¤¤Ï¤´¾µÃΤȻפ¤¤Þ¤¹¤¬¡¢Ç°¤Î¤¿¤á¡£


³¤ÇϤϵ­²±¤òÄêÃ夵¤»¤¿¤êµ­²±¤ò¸Æ¤Óµ¯¤·¤¿¤ê¤¹¤ëµ­²±¤ÎÅý¹ç´ï´±¤Ç¤¢¤ê


¤Þ¤¿³¤ÇϤÏÀ¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤Èž¤¸¤ë¥¹¥¤¥Ã¥Á¤Ç¤â¤¢¤ë¡£


²Ã¤¨¤Æ³¤ÇϤÏÂç¿Í¤Ç¤¢¤Ã¤Æ¤â¥Ë¥å¡¼¥í¥ó¤¬¿·À¸¤·¡¢°é¤Ä¾ì½ê¡£




¡Ö Ǿ¤Î¥â¥Î¥¢¥ß¥ó»À²½¹ÚÁÇ ( MAO ) ³èÀ­¤òÄã²¼¤µ¤»¤ë ¡×(9)


MAO ( ¥â¥Î¥¢¥ß¥ó¥ª¥­¥·¥À¡¼¥¼ ) Á˳²Ìô¤ÏǾ¤Î¥É¡¼¥Ñ¥ß¥óÇ»ÅÙ¤ò¾å¤²¤ë¡£


MAOÁ˳²Ìô¤Ï¡¢¥¢¥á¥ê¥«¤Ç¤Ï¹³¤¦¤ÄºÞ¤È¤·¤Æ¤â»È¤ï¤ì¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£


¤³¤ì¤¹¤Ê¤ï¤Á¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Î¹³¤¦¤ÄºîÍѤò¼¨¤¹Êó¹ð¤Ç¤¹¡£




3 ¥Ë¥å¡¼¥í¥ó¤Î¥¢¥Ý¥È¡¼¥·¥¹¤Ø¤ÎºîÍÑ


¡Ö ¥Ë¥å¡¼¥í¥ó¤Î¥¢¥Ý¥È¡¼¥·¥¹¤Î¸º¾¯ ¡×(10)¡¨(11)¡¨(12¡Ë


¥¢¥Ý¥È¡¼¥·¥¹¤È¤Ï¥×¥í¥°¥é¥à¤µ¤ì¤¿ºÙ˦¤Î»àÌÇ¡¢ºÙ˦¤Î¼«»¦¤È¸À¤ï¤ì¤ë¸½¾Ý¤Ç¡¢¥Ë¥å¡¼¥í¥ó»àÌǸ¶°ø¤Î¤Ò¤È¤Ä¡£




4 ǧÃε¡Ç½¡¢µ­²±¤Ø¤Î¸ú²Ì


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤ÎÉÕÃå¤ò²þÁ±¤¹¤ë¤È¤âÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£


¡Ö ¿À·Ð²êºÙ˦¼ðºÙ˦¤Ë¤ª¤±¤ë¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Î¶Å½¸ÍÞÀ© ¡×(11)


¡Ö °Õ»×·èÄêǽÎϤä¹âÎðưʪ¤Ë¤ª¤±¤ë¿·¤·¤¤¥¹¥­¥ë¤Î½¬ÆÀ¡¢¥¹¥È¥ì¥¹¤Ø¤Î±þÅú¤äµ¤Ê¬¤ÎÊѲ½¤È¤¤¤Ã¤¿°ø»Ò¤ËÂФ·¤ÆÍ­±× ¡×(9)¡§(13)


£Ä£Î£Á¤¬Â»½ý¤ò¼õ¤±¡¢°Û¾ï¤Ê¥«¥¿¥Á¤Î¥¿¥ó¥Ñ¥¯¼Á¤òºî¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£


¤¿¤È¤¨¤ÐǾÆâ¤Ë¤ª¤¤¤Æ¤Ï¡¢¥¿¥ó¥Ñ¥¯¼Á¤ÎÀ½Â¤¤Î²áÄø¤Ç¡¢ËÜÍè¡¢Æ⦤ËÀޤꤿ¤¿¤Þ¤ì¤ë¤Ù¤­ÌýÀ­Éôʬ¤¬³°¤Ë¤à¤­½Ð¤·¤È¤Ê¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£


¤½¤ì¤é°Û¾ï¤Ê¥¿¥ó¥Ñ¥¯¼ÁƱ»Ö¤ÏÌþÃ夷¡¢²ô¤È²½¤·¤Æ¤æ¤¯¡£


¤³¤Î²ô¤Ï¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤È¸Æ¤Ð¤ì¤Þ¤¹¡£


¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Ï¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤θ¶°ø¤Î¤Ò¤È¤Ä¤È¤â¸«¤é¤ì¤Æ¤¤¤Þ¤¹¡£


¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤¬ÉÕÃ夷¤¿¥Ë¥å¡¼¥í¥ó¤Ï¤ä¤¬¤Æ¿ê¼å¤·¡¢»àÌǤ¹¤ë¤³¤È¤¬Ê¬¤«¤Ã¤Æ¤¤¤Þ¤¹¡£


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¤½¤Î¿ê¼åÃʳ¬¤Ë¤¢¤ë¥Ë¥å¡¼¥í¥ó¤ò²óÉü¤µ¤»¤ë¤È¤ÎÊó¹ð¤â¤¢¤ê¤Þ¤¹¡£


¾åµ­¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤¬¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Î·ÁÀ®¤òÍÞÀ©¤¹¤ë¤È¤¤¤¦Êó¹ð¤Ç¤¹¡£


¤Á¤Ê¤ß¤Ë¤³¤Î¥ì¥Ó¥å¡¼¤Ë¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Îµ­²±ÎϲþÁ±ºîÍѤòÊó¹ð¤¹¤ëÏÀʸ¤Î°úÍѤϤ¢¤ê¤Þ¤»¤ó¤¬¡¢¤½¤Î²ÄǽÀ­¤ò¼¨¤¹ÏÀʸ¤ò¸«¤Ä¤±¤ë¤³¤È¤Ï¤Ç¤­¤Þ¤¹¡£


ʬ»Ò¥ì¥Ù¥ë¤Ç¤Ï¡¢¤¿¤È¤¨¤Ð NDMA¼õÍÆÂΡÊĹ´üµ­²±¤Ë´Ø·¸¤¹¤ë¼õÍÆÂΡˤΥΥ寥¢¥¦¥È¥Þ¥¦¥¹¤Ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤òÍ¿¤¨¡¢µ­²±ÎϤ¬Ìá¤Ã¤¿Åù¡¢Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£




5 ·ì±Õ¡¢·ìή¡¢·ì´É¤Ø¤ÎºîÍÑ


¡Ö ·ì¾®ÈijèÀ­²½°ø»Ò PAF ÍÞÀ©¸ú²Ì¤Ë¤è¤ëǾµõ·ì¤Î²þÁ± ¡×(10)


¡Ö ÆâÈéͳÍè·ì´ÉÃд˰ø»Ò EDRF (Stimulation of endothelium-derivedrelaxing factor) ¤Î»É·ã¤Ë¤è¤ëÆ°Ì®¡¢ÀÅÌ®¤ª¤è¤ÓÌӺٴɤν۴IJþÁ± ¡×(14)


·ì´É¤Î¤â¤Ã¤È¤âÆ⦤˸ºß¤¹¤ëÆâÈé¤ÏÍÍ¡¹¤Êʪ¼Á¤òʬÈ礷¤Þ¤¹¡£


EDRF (NO °ì»À²½ÃâÁÇ) ¤â¤½¤Î¤¦¤Á¤Î¤Ò¤È¤Ä¡£


°ì»À²½ÃâÁǤϷì´É¤òÃдˤµ¤»¤ë¡£


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤¬·ìή¤òÎɤ¯¤¹¤ë¤È¤¤¤¦¤Î¤Ï¤³¤Î¤¿¤á¤È¹Í¤¨¤é¤ì¤ë¡£




5 ¿À·ÐÅÁãʪ¼Á¤Ø¤ÎºîÍÑ


¡Ö ǾÆâ¤Î¦Á1-¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂΡ¢5-HT1A ( ¥»¥í¥È¥Ë¥ó ) ¼õÍÆÂΤª¤è¤Ó¥à¥¹¥«¥ê¥ó¼õÍÆÂΤÎǯÎð¤Ë¤è¤ë¸º¾¯Í½ËÉ ¡×(6)


¡Ö ³¤ÇϤιâ¿ÆÏÂÀ­¥³¥ê¥ó¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤Î¼è¤ê¹þ¤ß¤ÎÁý²Ã ¡×(6)


¥·¥Ê¥×¥¹Á°ºÙ˦¤«¤éÊü½Ð¤µ¤ì¤¿¥¢¥»¥Á¥ë¥³¥ê¥ó¤Ï¡¢¥·¥Ê¥×¥¹¸åºÙ˦¤Î¼õÍÆÂΤò³èÀ­²½¤·¤¿¤¢¤È¤Ç¡¢µÞ®¤Ëʬ²ò¤µ¤ì¤Þ¤¹¡£ ¥³¥ê¥ó¥¨¥¹¥Æ¥é¡¼¥¼¤Ë¤è¤Ã¤Æ¥³¥ê¥ó¤È¿Ý»À¤Ë¡£


¥·¥Ê¥×¥¹¤Ï¿®¹æÅÁã¤ò¤¹¤ë¤¿¤á¤Ë¥¢¥»¥Á¥ë¥³¥ê¥ó¤òºÆÅÙ¡¢ÊÝÍ­¤·¤Ê¤±¤ì¤Ð¤Ê¤ê¤Þ¤»¤ó¡£


¤·¤«¤·¥Ë¥å¡¼¥í¥ó¤Ï¥¢¥»¥Á¥ë¥³¥ê¥ó¤Î¸¶ÎÁ¤Ç¤¢¤ë¥³¥ê¥ó¤òºî¤ì¤Þ¤»¤ó¤Î¤Ç¡¢Ê¬²ò¤µ¤ì¤Æ¼þ°Ï¤òɺ¤¦¥³¥ê¥ó¤ò¡¢ºÆÅÙ¡¢¥·¥Ê¥×¥¹Æâ¤Ë¼è¤ê¤³¤àɬÍפ¬¤¢¤ê¤Þ¤¹¡£


³¤ÇϤιâ¿ÆÏÂÀ­¥³¥ê¥ó¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤È¤Ï¡¢¤½¤ì¤é¥³¥ê¥ó¤Î¼è¤ê¹þ¤ß¸ý¤Î¤³¤È¤Ç¤¹¡£


¤Ä¤Þ¤ê¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¥¢¥»¥Á¥ë¥³¥ê¥ó¤òÁý¤ä¤¹¤è¤¦¤Ç¤¹¡£¡Ê¥³¥ê¥ó¤Î¥ê¥µ¥¤¥¯¥ë¸úΨ¤ò¸þ¾å¤µ¤»¤ë¡Ë¡Ê¤Á¤Ê¤ß¤Ë¹âÎï¿Í»²¥¨¥­¥¹¤Ë¤â¤³¤ÎƯ¤­¤¬¤¢¤ê¤Þ¤¹¡Ë


¥¢¥»¥Á¥ë¥³¥ê¥ó¤Ï¡¢µ­²±¤Î·ÁÀ®¡¢³Ø½¬¡¢¹ÔÆ°¡¢¿ç̲¤Ë´Ø·¸¤¹¤ë¿À·ÐÅÁãʪ¼Á¤Ç¤¢¤ë¤³¤È¤Ï¤´¾µÃΤ«¤È»×¤¤¤Þ¤¹¡£




7 ¹³¥¹¥È¥ì¥¹ºîÍÑ¡¢°äÅÁ»Òȯ¸½¤Ø¤ÎºîÍѤʤÉ


¡Ö ³¤ÇϤΥ°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤΥÀ¥¦¥ó¥ì¥®¥å¥ì¡¼¥·¥ç¥ó¤ÎÁ˳² ¡×(6)


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¡¢¥¹¥È¥ì¥¹¤Ø¤ÎÄñ¹³ÎϤò¹â¤á¤ë¤È¤¤¤¦Êó¹ð¡£


³¤ÇϤΥ°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤθº¾¯¤ò¤¯¤¤¤È¤á¤ë¤È¤¤¤¦¤³¤ÎºîÍѤϡ¢¤¢¤ë¼ï¤Î¹³¤¦¤ÄÌôƱÍͤÎƯ¤­¡£


¥°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤȤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤǤ¹¡£


¤½¤Î¼õÍÆÂΤγèÀ­²½¤È¤Ï¡¢À¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤ÈÀÚ¤êÂؤ¨¤ë¤¿¤á¤Ë½ÅÍס£


³¤ÇϤˤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤ¬Â¿¤¯¤¢¤ê¡¢¤½¤ì¤æ¤¨²á¾ê¤Ê¥³¥ë¥Á¥¾¡¼¥ë¤Ï³¤ÇϤòÇ˲õ¤¹¤ë¤È¤¤¤¦¤Î¤¬Àè¤Û¤É¤Î¤ªÏä·¡£




¡Ö ¤¢¤ëÆÃÄê¤Î°äÅÁ»Ò¤Îž¼Ì¤òÄ´À᤹¤ë¡£¤½¤Î·ë²Ì¡¢ºÙ˦¤Î¹³»À²½¾õÂÖ¤òÁý²Ã¤µ¤»¡¢»À²½¥¹¥È¥ì¥¹ÂÑÀ­¤ò¶¯²½¡¢ÅÁ㥢¥»¥Á¥ë¥³¥ê¥ó¤ÎÎ̤âÁý¤¨¤ë¡×(15)


¡Ö DNA¹çÀ®¤ä½¤Àµ¡¢ºÙ˦¼þ´ü¤Ë¤ª¤±¤ëµ¡Ç½¤Ë´Ø¤ï¤ë¥¿¥ó¥Ñ¥¯¼Á¤ÎÊѲ½¤Ë±Æ¶Á¤ò¤¢¤¿¤¨¡¢DNA»½ý¤òÍÞÀ©¤¹¤ë¡×(15)


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï°äÅÁ»Òȯ¸½¤ËºîÍѤ·¡¢¹³»À²½ÎϤζ¯¤¤¥Ë¥å¡¼¥í¥ó¤Ë¶¯²½¤¹¤ëƯ¤­¤òÍ­¤¹¤ë¡£




8 ¤½¤Î¾


¡Ö ¥ß¥È¥³¥ó¥É¥ê¥¢¤Î¸ÆµÛÄ´ÀáÈæΨ¤ÎÁý²Ã¤Ë¤è¤ëATP¥ì¥Ù¥ë¤òÁý²Ã ¡×(1)


¤³¤ì¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤ÏÀ¸ÂÎÆâ¤Î¥¨¥Í¥ë¥®¡¼¤òÁý¤ä¤¹¤È¤¤¤¦Êó¹ð¡£


¤Û¤«¤Ë¤â¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¹â»³É¤ËÍ­¸ú¤Ç¤¢¤ë¤È¤¤¤¦Êó¹ð¤â¤¢¤ë¡£


¤³¤ì¤¬°ÕÌ£¤¹¤ë¤Î¤Ï»ÀÁǤμè¤ê¹þ¤ß¸úΨ¤ò¾å¤²¤ë¤È¤¤¤¦¤³¤È¤Ç¤¹¡£


Æü¾ïÀ¸³è¤Î¤Ê¤«¤Ç¤â»ÀÁǤμè¤ê¹þ¤ß¤Î¸º¤ë»öÂ֤Ϥ¿¤Ó¤¿¤ÓÀ¸¤¸¤Þ¤¹¡£


½¸Ã椹¤ë¤È¤­¡¢¤ï¤¿¤·¤¿¤Á¤Ï¸ÆµÛ¤ò¤Ä¤¤Ëº¤ì¤¬¤Á¡£


½¸Ã椷¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤È¤­¤Ë¤Ï¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤òÀݤê¤Þ¤·¤ç¤¦¡£










½¸Ã椹¤ë»Å»öXSmall












¡Ö ¹³±ê¾ÉºîÍѤª¤è¤ÓǾ¾ã³²¤ËÂФ¹¤ëÊݸîºîÍÑ ¡×(16)


¡Ö ¿À·Ð¤Î²ÄµÕÀ­¤Ø¤Î±Æ¶Á ¡×(6)¡¨(3)


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Ï¼å¤Ã¤¿¥Ë¥å¡¼¥í¥ó¤ò²óÉü¤µ¤»¤ë¤è¤¦¤Ç¤¢¤ë¡£






¤·¤«¤·¤³¤³¤Ç¤ÎÌäÂê¤Ï¡¢¥Õ¥Ä¥¦¤Î¤Ò¤È¡¢¤Ç¤Ï¤Ê¤¯¡¢Æ¬Ç¾Àï»Î¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Î¥Ý¥Æ¥ó¥·¥ã¥ë¤ò¤É¤¦°ú¤­½Ð¤¹¤«¡¢¤È¤¤¤¦¤³¤È¤Ç¤·¤ç¤¦¡£


¤ª´«¤á¤¹¤ë¤Î¤Ï¡¢¹âÎï¿Í»²¥¨¥­¥¹¤ä¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤ÈÁȤ߹ç¤ï¤»¤ë¤³¤È¤Ç¤¹¡£


¹âÎï¿Í»²¥¨¥­¥¹¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹Æ±ÍÍ¡¢¡Ö¶½Ê³ÆÇÀ­»à¡×¤òÍÞ¤¨¤ëƯ¤­¡¢¥¢¥»¥Á¥ë¥³¥ê¥ó¤òÁý¤ä¤¹Æ¯¤­¤â´üÂԤǤ­¤Þ¤¹¡£


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤ÈÁȤ߹ç¤ï¤»¤¿¼Â¸³¤Ç¤Ï¡¢ADHD¤ò²þÁ±¤¹¤ëÊó¹ð¤â¤µ¤ì¤Æ¤¤¤Þ¤¹¡£


½¸ÃæÎϤò¹â¤á¤ë¤³¤È¤¬´üÂԤǤ­¤ë¤Î¤Ç¤¹¡£



¤µ¤é¤Ë¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤ÎÁȤ߹ç¤ï¤»¤Ë¤Ï¡¢½¸ÃæÎÏ¡¢µ­²±ÎϤò²þÁ±¤µ¤»¤ë¤³¤È¤âÊó¹ð¤â¤µ¤ì¤Æ¤¤¤Þ¤¹¡£


¤½¤ì¤é¥µ¥×¥ê¥á¥ó¥È¤ò¸ÄÊ̤˹ØÆþ¤·¡¢¼«Ê¬¤Ë¹ç¤¦¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¡¦¥¹¥¿¥Ã¥¯¤ò¸«¤Ä¤±¤Æ¤ß¤Æ¤Ï¤¤¤«¤¬¤Ç¤·¤ç¤¦¤«¡£


¤¢¤ë¤¤¤Ï


¥­¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH ¤ä¡¢¥¯¡¼¥ë¥¹¥¦¥£¥Ã¥Á COOL SWITCH¤Ë¤Ï¡¢¤½¤ì¤éÊó¹ð¤È¤Û¤ÜƱÎ̤Υ¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¡¢¹âÎï¿Í»²¥¨¥­¥¹ (COOL SWITCH¤Ï¥¢¥á¥ê¥«¿Í»²)¡¢¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¡¢¥Ð¥³¥Ñ¥â¥Ë¥¨¥é¥¨¥­¥¹¤¬Ç۹礵¤ì¤Æ¤¤¤Þ¤¹¡£


¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤òñÆȤÇÀݤë¾ì¹ç¤È¡¢¥­¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH ¡¢COOL SWITCH ¤È¤ò°û¤ßÈæ¤Ù¤Æ¤ß¤ë¤Æ¤âÌÌÇò¤¤¤«¤â¤·¤ì¤Þ¤»¤ó¡£

¥¹¥¦¥£¥Ã¥Á¤Ï¡¢¥¢¥Þ¥¾¥ó¤ä³ÚÅ·¤Ç¤âÆþ¼ê¤Ç¤­¤Þ¤¹¡£

¢§¥¢¥Þ¥¾¥ó COOL SWITCH
https://www.amazon.co.jp/dp/B07P9XSK2G/

¢§¥¢¥Þ¥¾¥ó SWITCH
https://www.amazon.co.jp/dp/B0095GON76

¢§¥¢¥Þ¥¾¥ó HYPER SWITCH
https://www.amazon.co.jp/dp/B012QKWVMQ

¿·switch %282%29

cool_switch01ÀÚ¼èÇò ºÇÇò



References
(1)¡¡Defeudis FV (2002a) Bilobalide and Neuroprotection. Pharmacol

Res 46:565¡Ý568

(2)¡¡Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M (2002)Ginkgo biloba extract: from molecular mechanisms to the
treatment of Alzheimer's disease. Cell Mol Biol 48:613¡Ý623

(3)¡¡Gohil K, Packer L (2002) Global gene expression analysis identifiescell and tissue specific actions of Ginkgo biloba extract, EGb761. Cell Mol Biol 48:625¡Ý631

(4)¡¡Oken B, Storzbach D, Kaye J (1998) The efficacy of Ginkgo bilobaon cognitive function in Alzheimer disease. Arch Neurol55:1409¡Ý1415

(5)¡¡Ni Y, Zhao B, Hou J, Xin W (1996) Preventive effect of Ginkgobiloba extract on apoptosis in rat cerebellar neuronal cellsinduced by hydroxyl radicals. Neurosci Lett 214:115¡Ý118

(6)¡¡DeFeudis F, Drieu K (2000) Ginkgo biloba extract (EGb 761) andCNS functions: basic studies and clinical applications. CurrDrug Targets 1:25¡Ý58

(7)¡¡Lien E, Ren S, Bui H, Wang R (1999) Quantitative structure-activityrelationship analysis of phenolic antioxidants. Free Radic BiolMed 26:285¡Ý294

(8)¡¡Smith J, Luo Y (2003) Elevation of oxidative free radicals inAlzheimer's disease models can be attenuated by Ginkgo bilobaextract EGb 761. J Alzheimer's Dis 5:287¡Ý300

(9)¡¡Pardon M, Joubert C, Perez-Diaz F, Christen Y, Launay J, Cohen-Salmon C (2000) In vivo regulation of cerebral monoamineoxidase activity in senescent controls and chronically stressedmice by long-term treatment with Ginkgo biloba extract (EGb761) Mech Ageing Dev 113:157¡Ý68

(10)¡¡Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, QuirionR (2000) The Ginkgo biloba extract (EGb 761) protectshippocampal neurons against cell death induced by betaamyloid.Eur J Neurosci 12:1882¡Ý1890

(11)¡¡Luo Y, Smith J, Paramasivam V, Burdick A, Curry K, Buford J,Khan I, Netzer W, Xu H, Butko P (2002) Inhibition of amyloidbetaaggregation and caspase-3 activation by the Ginkgo bilobaextract EGb761. Proc Natl Acad Sci USA 99:12197¡Ý12202

DeFeudis FV (1998) Ginkgo biloba extract (EGb 761): fromchemistry to clinic. Ullstein, Weisbaden, Germany

(12)¡¡Smith J, Burdick A, Golik P, Khan I, Wallace D, Luo Y (2002) Antiapoptoticproperties of Ginkgo biloba extract EGb 761 indifferentiated PC12 cells. Cell Mol Biol 48:699¡Á707

(13)¡¡Cohen-Salmon C, Venault P, Martin B, Raffalli-Sebille M, BarkatsM, Clostre F, Pardon M, Christen Y, Chapouthier G (1997)Effects of Ginkgo biloba extract (EGb 761) on learning andpossible actions on aging. J Physiol 91:291¡Ý300

(14)¡¡Smith P, Maclennan K, Darlington C (1996) The neuroprotectiveproperties of the Ginkgo biloba leaf: a review of the possiblerelationship to platelet-activating factor (PAF) J Ethnopharmacol50:131¡Ý139

(15)¡¡DeFeudis FV (2002b) Effects of Ginkgo biloba extract (EGb 761)on gene expression: possible relevance to neurologicaldisorders and age-associated cognitive impairment. Drug DevRes 57:214¡Ý235

(16)¡¡Oberpichler H, Sauer D, Rossberg C, Mennel HD, Krieglstein J(1990) PAF antagonist ginkgolide B reduces postischemicneuronal damage in rat brain hippocampus. J Cereb Blood FlowMetab 10:133¡Ý135

¥¹¥È¥ì¥¹¤ËÂǤÁ¤Î¤á¤µ¤ì¤Æ¤¤¤Þ¤»¤ó¤«¡©


¢£ ºîÀï


µÞÀ­¥¹¥È¥ì¥¹¤Ë¤Ï¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹

ËýÀ­¥¹¥È¥ì¥¹¤Ë¤Ï¡¢¹âÎï¿Í»²¥¨¥­¥¹¤ò»È¤¤¤Þ¤·¤ç¤¦¡£


²¼µ­¤Î¸¦µæ¤Ï¤½¤Î¤³¤È¤òÊó¹ð¤·¤Æ¤¤¤Þ¤¹¡£
https://www.ncbi.nlm.nih.gov/pubmed/14737017



¤·¤«¤·¡¢¤½¤ÎÈ¿ÂФǤϸú²Ì¤¬¤Ê¤¤¤«¤â¤·¤ì¤Þ¤»¤ó¡£

µÞÀ­¤Ø¤Î¹âÎï¿Í»²¤ä¡¢ËýÀ­¤Ø¤Î¥¤¥Á¥ç¥¦ÍդǤϡ¢¸ú²Ì¤ò¼¨¤µ¤Ê¤¤¤è¤¦¤Ç¤¹¡£




¤½¤·¤Æ¤â¤¦¤Ò¤È¤Ä´Î¿´¤Ê¤È¤³¤í¡¢¤½¤ì¤é¤Î¿¢Êª¥¨¥­¥¹

¤¢¤é¤«¤¸¤áÀݤ俤¦¤Ç¤Î·ë²Ì¤Ç¤¹¡£

( ·Þ¤¨·â¤Ä¡¢¤È¤¤¤¦¥ï¥±)




¿Í´Ö¼Ò²ñ¤ËÀ¸¤¸¤ë¥¹¥È¥ì¥¹¤Ï¡¢¥é¥Ã¥È¤Î¤½¤ì¤è¤ê¤µ¤é¤ËÊ£»¨¡£


ËýÀ­¤«¤Ä¡¢µÞÀ­¡£


½ý¸ý¤Ë±ö¤Ï¤Ì¤é¤ì¤ë¤Ï


Ƨ¤Þ¤ì¤ë¤Ï¡¢½³¤é¤ì¤ë¤Ï¡£


¤½¤ó¤ÊÌܤâÅö¤Æ¤é¤ì¤Ê¤¤¥¹¥È¥ì¥¹¤âÄÁ¤·¤¯¤Ê¤«¤Ã¤¿¤ê¡¢¤Ç¤Ï¡¢¥¹¥È¥ì¥¹¤ÎȬÊý¤Õ¤µ¤¬¤ê¤ò¤«¤¤¤¯¤°¤ë¤¿¤á¤ÎºîÀï¤È¤Ï¡©



¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¹âÎï¿Í»²¥¨¥­¥¹¤Ï¤¤¤Ã¤·¤ç¤ËÀݤ뤳¤È¤¬¤Ç¤­¤Þ¤¹¡£



¤à¤·¤í¿˻¤Ê¤Ò¤È¤Ë¤Ï¤½¤ì¤¬Îɤ¤¤Ç¤·¤ç¤¦¡£


¤½¤ÎÆó¤Ä¤Î¿¢Êª¥¨¥­¥¹¤ÎÁȤ߹ç¤ï¤»¤Ï¡¢Ãí°ÕÎÏ¡ÊADHD¡Ë¤Î²þÁ±¤â´üÂԤǤ­¤ë¤«¤â¤·¤Ê¤¤¤«¤é¤Ç¤¹¡£
https://www.ncbi.nlm.nih.gov/pubmed/11394191


¥­¥í¥ó¤Î SWITCH ¤Ë¤Ï

¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¹âÎï¿Í»²¥¨¥­¥¹¤¬´Þ¤Þ¤ì¤Æ¤¤¤Þ¤¹¡£(COOL SWITCH ¤Ë¤Ï¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹¡¢¤³¤Á¤é¤ÏÄãǯÎð¡¢¹âǯÎð¤Ë¤â¹ç¤¦¤Î¤Ç¤Ï¤Ê¤¤¤Ç¤·¤ç¤¦¤«)

É餱¤é¤ì¤Ê¤¤¥ï¡¼¥«¡¼¤Ï SWITCH ¡¢COOL SWITCH »î¤µ¤ì¤Æ¤ß¤Æ¤Ï¤¤¤«¤¬¤Ç¤·¤ç¤¦¤«¡£

SWITCH¤ÏAmazon¤ä³ÚÅ·¤Ç¤âÆþ¼ê¤Ç¤­¤Þ¤¹¡£
¿·switch %282%29

¢§Amazon¤Î¥Ú¡¼¥¸
https://www.amazon.co.jp
¤è¤ê¥Ñ¥ï¥Õ¥ë¤ÊËɸæ¤Ë¤ÏHYPER SWITCH¤òÁª¤Ö¤È¤¤¤¦¼ê¤â¡£

¥¤¥Á¥ç¥¦ÀÄXSmall

¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¿Í»²¥¨¥­¥¹ ¡Ê¥¢¥á¥ê¥«¿Í»²¤«¹âÎï¿Í»²¡Ë¤ÎÁȤ߹ç¤ï¤»¤¬ ADHD ¤ò´ËϤµ¤»¤¿¤È¤ÎÊó¹ð¤ò¡¢´Êñ¤Ë¤Ç¤¹¤¬¡¢¤´¾Ò²ð¤¤¤¿¤·¤Þ¤·¤ç¤¦¡£



¡Ö¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹¡ÊPanax quinquefolium¡Ë¡Ê200mg¡Ë ¤È¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¡Ê50mg¡Ë ¤Î

Ê£¹ç¥Ï¡¼¥ÖÀ½ºÞ ¡ÊAD-FX;CV Technologies¡¢¥¨¥É¥â¥ó¥È¥ó¡¢Alta.¡Ë ¤ÎÃí°Õ·çǡ¿ưÀ­¾ã³² ¡ÊADHD¡Ë¤Îħ¸õ¤ò²þÁ±¤¹¤ë¤½¤ÎǽÎϤò»î¸³¤·¤Þ¤·¤¿¡×

https://www.ncbi.nlm.nih.gov/pubmed/?term=11394191



·ëÏÀ¡§

¡Ö¤³¤ì¤é¤Î·ë²Ì¤Ï AD-FX ÅêÍ¿¤¬ ADHD ¤Î¾É¾õ¤ò²þÁ±¤¹¤ë²ÄǽÀ­¤¬¤¢¤ê¡¢¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹¤È¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤Î»ÈÍѤι¹¤Ê¤ë¸¦µæ¤ò¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤³¤È¤ò¼¨º¶¤·¤Þ¤¹¡×



¤³¤Î¼Â¸³¤Ç»È¤ï¤ì¤Æ¤¤¤ë¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹¤Ï¡¢¤³¤ì¤òÆüËܤǤâÎɤ¯ÃΤé¤ì¤Æ¤¤¤ë¹âÎï¿Í»²¥¨¥­¥¹¤ËÂؤ¨¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

¼çÍפʳèÀ­À®Ê¬¤¬Æ±¤¸¤À¤«¤é¤Ç¤¹¡£


ADHD ¤ò²þÁ±¤·¤¿¤¤Êý¤Ï¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹¤È¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹¡¢¤Þ¤¿¤Ï¹âÎï¿Í»²¥¨¥­¥¹¤ÎÁȤ߹ç¤ï¤»¤ò»î¤·¤Æ¤ß¤Æ¤Ï¤¤¤«¤¬¤Ç¤·¤ç¤¦¤«¡£



ÆüËÜÀ½¤Î¥µ¥×¥ê¥á¥ó¥È¤Ç¤ªµá¤á¤Ê¤é¡¢

¥­¥í¥ó¤Î SWITCH ¤«

2019ǯ¤ËȯÇ䤵¤ì¤¿ COOL SWITCH ¤¬Îɤ¤¤Ç¤·¤ç¤¦¡£

¤¢¤ë¤¤¤Ï¡¢2020ǯ¤ËȯÇ䤵¤ì¤¿¥­¥í¥ó¤Î DAMPER ¤Ë¤Ï¡¢¾åµ­¤·¤¿¸¦µæ¤ÈƱ¤¸Ê¬ÎÌ¡Ê¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹200mg ¤È ¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹50mg¡Ë¤¬´Þ¤Þ¤ì¤Æ¤¤¤ë¤Î¤Ç¡¢¤³¤ì¤âÎɤ¤¤Ç¤·¤ç¤¦¡£


SWITCH ¤Ë¤Ï¡¢

¥¤¥Á¥ç¥¦ÍÕ¥¨¥­¥¹
¹âÎï¿Í»²¥¨¥­¥¹
¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¥Ñ¥³¥Ñ¥â¥Ë¥¨¥é¥¨¥­¥¹¤¬

ºÇŬÎ̤ÇÇ۹礵¤ì¤Æ¤¤¤Þ¤¹¡£


COOL SWITCH ¤Ï¡¢

¹âÎï¿Í»²¥¨¥­¥¹¤Î¤È¤³¤í¤¬¡¢

¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹¤Ë¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£

¥¢¥á¥ê¥«¿Í»²¥¨¥­¥¹¤Ï¡¢10Âå¡¢¹âǯÎ𡢤Τܤ»¤ä¤¹¤¤¿Í¤Ë¹ç¤¤¤ä¤¹¤¤¤«¤â¤·¤ì¤Þ¤»¤ó¡£

iStock_000011839672XxSmall

SWITCH ¡¢COOL SWITCH ¡¢DAMPER ¤Ï¡¢¥¢¥Þ¥¾¥ó¤ä³ÚÅ·¤Ç¤â¼ê¤ËÆþ¤ê¤Þ¤¹¡£

¢§¥¢¥Þ¥¾¥ó COOL SWITCH
https://www.amazon.co.jp/dp/B07P9XSK2G/

¢§¥¢¥Þ¥¾¥ó SWITCH
https://www.amazon.co.jp/dp/B0095GON76

¢§¥¢¥Þ¥¾¥ó DAMPER
https://www.amazon.co.jp/dp/B08J28C2TM

¿·switch %282%29

cool_switch01ÀÚ¼èÇò ºÇÇò





¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¥Ø